Novorapid 100IU Injection

Introduction

Novorapid is a prescription medication that contains the active ingredient Insulin Aspart. It is available under the brand name Novorapid. This medication is commonly used in the treatment of diabetes mellitus.

Uses

Novorapid is primarily prescribed to help manage blood sugar levels in individuals with diabetes. It is commonly used for both type 1 and type 2 diabetes. This medication helps control blood sugar levels and prevents complications associated with high blood sugar.

Dosage and Administration

The dosage of Novorapid will vary depending on individual needs and the advice of your healthcare provider. Follow the instructions provided by your healthcare professional. This medication is typically administered via subcutaneous injection. Your healthcare provider will guide you on the correct technique for injecting the medication.

Mechanism of Action

Insulin Aspart, the active ingredient in Novorapid, works by replacing the insulin that is normally produced by the pancreas. It helps lower blood sugar levels by facilitating the uptake of glucose from the bloodstream into cells, where it can be used for energy or stored for future use.

Side Effects

Common side effects may include injection site reactions, such as redness, swelling, or itching. Other common side effects may include hypoglycemia (low blood sugar), weight gain, and fluid retention.

In some cases, serious side effects may occur. These can include allergic reactions, difficulty breathing, swelling of the face or throat, and severe hypoglycemia. If you experience any serious or persistent side effects, seek medical attention immediately.

Drug Interactions

inform your healthcare provider about all the medications you are currently taking, including prescription drugs, over-the-counter medications, and herbal supplements. Drug interactions can occur when certain medications interact with Novorapid, potentially affecting its effectiveness or causing side effects. It is especially important to discuss with your healthcare provider if you are taking other medications that can affect blood sugar levels, such as certain oral antidiabetic drugs or beta-blockers.

Precautions

Before using Novorapid. Inform your healthcare provider about any medical conditions you have, including liver or kidney problems, heart disease, or any other serious health conditions. Inform your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding.

Novorapid is contraindicated in individuals with known hypersensitivity to Insulin Aspart or any of the other ingredients in the medication.

Storage

Novorapid should be stored in a refrigerator at a temperature between 2°C and 8°C (36°F and 46°F). Do not freeze the medication. Keep it out of the reach of children and pets. If the medication has been exposed to excessive heat or freezing temperatures, it should be discarded.

Patient Tips

• Always carry a source of fast-acting sugar, such as glucose tablets or candy, to treat episodes of low blood sugar (hypoglycemia) that may occur while using Novorapid.
• Follow your healthcare provider’s instructions regarding meal planning, physical activity, and blood sugar monitoring while using this medication.
• Keep track of your blood sugar levels regularly and report any significant changes or concerns to your healthcare provider.
• If you have any questions or concerns about using Novorapid, be sure to discuss them with your healthcare provider. They can provide you with personalized guidance and support.

Please note that this description, as well as the other content on our website is for educational purposes only. We do not provide medical advice. For specific medical advices, diagnoses and treatment options you should consult with your doctor.

References

• Type 1 diabetes – Managing insulin (NHS UK) [Accessed 14 Jun. 2024] (online) Available at:
• Fiasp 100 units/mL FlexTouch solution for injection in pre-filled pen (Health Professionals SmPC) Available at:
• Insulin aspart protamine Interactions (Drugs.com) [Accessed 16 Jun. 2024] (online) Available at:
• insulin aspar prt-insulin aspart 100 unit/ml (70-30) subcutaneous soln intermediate-, long-acting, and combination insulins (RX) [Accessed 13 Jun. 2024] (online) Available at:
• Insulin (Food and Drug Administration) [Accessed 26 Jun. 2024] (online) Available at:
• Rosenstock J, Emral R, Sauque-Reyna L, Mohan V, Trescolí C, Al Sifri S, Lalic N, Alvarez A, Picard P, Bonnemaire M, Demil N, McCrimmon RJ; SoliMix Trial Investigators. Advancing Therapy in Suboptimally Controlled Basal Insulin-Treated Type 2 Diabetes: Clinical Outcomes With iGlarLixi Versus Premix BIAsp 30 in the SoliMix Randomized Controlled Trial. Diabetes Care. 2021 Jun 28;44(10):2361-70. doi: 10.2337/dc21-0393. Online ahead of print. [Accessed 30 Jun. 2024] Available at: